对“PP2A 抑制使 BCR-ABL 人类白血病中的癌症干细胞对 ABL 酪氨酸激酶抑制剂敏感”一文的评论的回应。
Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
机构信息
Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC V5Z 1L3, Canada.
Department of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
出版信息
Sci Transl Med. 2019 Jul 17;11(501). doi: 10.1126/scitranslmed.aav0819.
PMID:31316004
Abstract
LB100 sensitizes resistant chronic phase CML stem and progenitor cells to TKIs and spares healthy bone marrow cells.
摘要
LB100 可增强 TKI 耐药慢性期 CML 干细胞和祖细胞的敏感性，并保护健康骨髓细胞。
相似文献
1
Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".对“PP2A 抑制使 BCR-ABL 人类白血病中的癌症干细胞对 ABL 酪氨酸激酶抑制剂敏感”一文的评论的回应。
Sci Transl Med. 2019 Jul 17;11(501). doi: 10.1126/scitranslmed.aav0819.
2
Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".评论“PP2A 抑制使 BCR-ABL 人类白血病中的癌症干细胞对 ABL 酪氨酸激酶抑制剂敏感”。
Sci Transl Med. 2019 Jul 17;11(501). doi: 10.1126/scitranslmed.aau0416.
3
PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia.PP2A 抑制使 BCR-ABL 人类白血病中的癌症干细胞对 ABL 酪氨酸激酶抑制剂敏感。
Sci Transl Med. 2018 Feb 7;10(427). doi: 10.1126/scitranslmed.aan8735.
4
Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.靶向慢性粒细胞白血病中的BLT2可抑制白血病干/祖细胞功能。
Biochem Biophys Res Commun. 2016 Apr 15;472(4):610-6. doi: 10.1016/j.bbrc.2016.03.018. Epub 2016 Mar 8.
5
Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.酪氨酸激酶抑制剂时代的慢性髓性白血病：分子靶向治疗的不断演变模式
Mol Diagn Ther. 2016 Aug;20(4):315-33. doi: 10.1007/s40291-016-0208-1.
6
The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.慢性髓性白血病CD34细胞对Bcr-Abl酪氨酸激酶抑制剂的敏感性受神经酰胺水平调节。
Leuk Res. 2016 Aug;47:32-40. doi: 10.1016/j.leukres.2016.05.010. Epub 2016 May 17.
7
Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia.慢性髓性白血病中肿瘤干细胞及干细胞耐药相关概念的临床研究进展
Leuk Lymphoma. 2008 Apr;49(4):604-9. doi: 10.1080/10428190801923212.
8
Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.C086 通过双重抑制 Bcr-Abl 和 Hsp90，有力地抑制了伊马替尼耐药 CML 细胞的增殖。
Clin Cancer Res. 2015 Feb 15;21(4):833-43. doi: 10.1158/1078-0432.CCR-13-3317. Epub 2014 Dec 11.
9
Quinacrine Depletes BCR-ABL and Suppresses Ph-Positive Leukemia Cells.喹吖因可消耗BCR-ABL并抑制Ph阳性白血病细胞。
Cancer Invest. 2019;37(6):242-252. doi: 10.1080/07357907.2019.1630633. Epub 2019 Jul 11.
10
BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.BCR-ABL1 通过 MYC 介导的 miR-150 下调导致慢性髓性白血病中的骨髓分化阻滞和耐药。
Haematologica. 2018 Dec;103(12):2016-2025. doi: 10.3324/haematol.2018.193086. Epub 2018 Jul 26.
引用本文的文献
1
Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia.慢性髓性白血病中酪氨酸激酶与磷酸酶相互作用的当前观点
Cancers (Basel). 2021 May 12;13(10):2311. doi: 10.3390/cancers13102311.
2
PP2A and tumor radiotherapy.蛋白磷酸酶 2A 与肿瘤放射治疗。
Hereditas. 2020 Aug 26;157(1):36. doi: 10.1186/s41065-020-00149-7.
Zotero 插件